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ABSTRACT 25 
Background: The incidence of oesophageal adenocarcinoma is increasing globally. Barrett’s 26 
oesophagus (BO) is a pre-malignant condition with no biomarker to risk stratify those at 27 
highest risk of dysplasia and malignant transformation. Methods: Subcellular epithelial 28 
protein (HMGB1, p53, RUNX3) expression, alongside expression of CD20, CD4, CD8 and Foxp3 29 
to characterise stromal B lymphocyte, and helper, cytotoxic and regulatory T-lymphocyte cell 30 
infiltrate, respectively, was assessed by immunohistochemistry in 218 human tissue samples 31 
including normal oesophageal/gastric biopsies (n=39), BO (non-dysplasia, dysplasia, non-32 
dysplastic background from progressors to dysplasia or cancer, n=121), and oesophageal 33 
adenocarcinoma (n=58). Results: There is a dynamic subcellular epithelial expression of 34 
HMGB1 (loss of nuclear, emergence of cytoplasmic), associated with epithelial p53 expression 35 
and differential immune cell phenotype in oesophageal neoplastic progression. We identify a 36 
protein signature and lymphocyte infiltrate in non-dysplastic BO when progressive disease 37 
(dysplasia or adenocarcinoma) is present but not histologically represented in the biopsied 38 
field. There is a dynamic stromal lymphocytic infiltrate in oesophageal neoplastic progression. 39 
Conclusions: This data reveals novel insights into the microenvironment of BO and 40 
progression towards cancer, and identifies a novel high risk biomarker of disease progression 41 
to aid surveillance strategies to identify early progression and impact future incidence of 42 
oesophageal cancer.  43 
 44 
 45 
  46 
3 
 
BACKGROUND 47 
The global incidence of oesophageal cancer is increasing with over half a million cases 48 
worldwide in 2018, accounting for 1 in 20 of all cancer deaths. In the UK,1 there are 9000 new 49 
cases per year with a 15% 5 year survival.2 Barrett’s oesophagus (BO) is a pre-malignant 50 
condition for oesophageal adenocarcinoma that affects 1.6-8% of the UK population.3 BO is 51 
defined by histological evidence of epithelial metaplasia from normal stratified squamous 52 
epithelium to mucin-secreting columnar epithelium in the distal oesophagus. These 53 
metaplastic cells can undergo further transformation to dysplasia or malignancy. Although 54 
the lifetime risk of transformation remains under debate, a previous UK study of nearly 8000 55 
patients suggested this could be as high as 1 in 14 patients, although a risk of approximately 56 
0.5% per annum has been more widely reported.4 The annual incidence of oesophageal 57 
adenocarcinoma is 0.33% and 1.40% in non-dysplastic and dysplastic BO, respectfully.5,6 58 
Cancer incidence has been estimated to be 40-times greater in high grade dysplasia, 59 
compared to the general population.7 Currently, it is not possible to predict those with BO at 60 
high risk of progression to dysplasia and malignancy. Therefore, all patients are offered 61 
interval endoscopic surveillance with biopsy to detect cell dysplasia or early cancer amenable 62 
to endoscopic therapy.8 This strategy carries significant resource implications and subjects 63 
individuals to repeated invasive investigation. There is clearly a clinical need to identify those 64 
at highest risk of progression at the point of diagnosis and to focus endoscopic and clinical 65 
resource accordingly. Currently, the pathogenesis of metaplastic-dysplastic-malignant 66 
progression is not fully understood.3,9 However, there have been a variety of proposed 67 
biomarkers to aid this risk stratification10, including transcriptional changes,11 tissue 68 
microRNAs12,13 or circulating glycoproteins14 and breath volatiles.15  69 
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Identifying novel cellular mechanisms that underlie BO pathogenesis and progression 70 
would identify biomarkers of risk, inform less invasive and more sensitive monitoring 71 
strategies and by detecting progressive disease early, impact incidence and prognosis of 72 
oesophageal cancer.  73 
With this clinical problem in mind, our aim was to define the role of the protein high 74 
mobility group box-1 (HMGB1) in BO and progression to cancer. Due to its cellular functions, 75 
and link to key protein targets, we hypothesized that HMGB1 is important in the pathogenesis 76 
of BO to cancer. HMGB1 is a ubiquitous nuclear protein that binds to the minor grove of DNA 77 
to stabilise the genome and regulate gene expression.16 Cellular stress results in 78 
phosphorylation of HMGB1, inducing cytoplasmic and extracellular shuttling.17 Once 79 
extracellular, HMGB1 influences epithelial cell behaviour and immune cell responses.18,19 80 
HMGB1 is differentially expressed in malignancy at a number of body sites, including liver, 81 
stomach, colon, bladder, pancreas, prostate and cervix. In squamous oesophageal cancer, 82 
HMGB1 promotes lymphangiogenesis by regulating expression of VEGF-C and VEGF-D, and is 83 
negatively correlated to survival.20 There is no data on expression of HMGB1 in BO or 84 
oesophageal adenocarcinoma.  85 
We propose that identifying important effector proteins, downstream of HMGB1, is 86 
key to fully characterising the role of HMGB1 in pre-malignant and malignant pathologies. 87 
p53 is a pivotal tumour suppressor protein that becomes dysregulated in various cancers.21 88 
In oesophageal adenocarcinoma, approximately 75% of patients have p53 mutations and 89 
consequently express strong nuclear p53.22 In BO, only foci of dysplasia exhibit p53. Some 90 
centres incorporate p53 expression as a diagnostic aid for identifying dysplasia.8 Of interest 91 
here, HMGB1 can facilitate p53-DNA binding, induce a p53-dependent senescent growth 92 
arrest, and complex with p53 to mediate autophagy and apoptosis; localisation and 93 
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expression of each protein influences the other.23–25 We hypothesise that loss of nuclear 94 
HMGB1 expression could impact p53 expression in oesophageal neoplastic progression.  95 
 Similarly, runt-related transcription factor 3 (RUNX3) is a highly-conserved 96 
transcription factor important in the activation, proliferation and differentiation of 97 
lymphocytes.26 Promoter hypermethylation of RUNX3 is associated with an increased risk of 98 
progression, as well as poorer survival in oesophageal cancer.27 Hypermethylation of RUNX3 99 
occurs as an early event in BO and is an independent risk factor for progression to dysplasia 100 
or oesophageal adenocarcinoma.28 HMGB1 has been identified as a potent inducer of an 101 
interferon-γ producing TH17 lymphocyte immune cell response, via regulation of transcription 102 
factors T-bet and RUNX3, leading to progression of atherosclerosis.29 Therefore, we 103 
hypothesise that RUNX3 may be an important downstream mediator influenced by HMGB1 104 
expression.  105 
HMGB1 also co-ordinates immune cell function, although this is not well 106 
characterised.30 The mechanisms by which extracellular HMGB1 influences immune activity 107 
is complex and dependant on post-translation modification status through direct interaction 108 
with transmembrane receptors such as RAGE or TLR-4, or via complex formation with co-109 
factors, such as binding to CXCR4 as a heterodimer with CXCL12, or binding to TLR9 via a 110 
complex with CpG-ODN.31 It it now known that there are many mechanisms directing HMGB1 111 
induced immune responses. It is universally recognised that stromal immune responses are 112 
an important aspect of carcinogenesis and one of the hallmarks of cancer.32 Despite this, to 113 
date there has been no exploration of the dynamic inflammatory cell microenvironment in 114 
BO. 115 
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The aim of this study was to define the expression of HMGB1, key downstream 116 
proteins and lymphocyte phenotype in oesophageal neoplastic progression from BO to 117 
dysplasia to oesophageal adenocarcinoma in human tissue samples.  118 
Here, by demonstrating emergence of cytoplasmic HMGB1, nuclear p53 and nuclear 119 
RUNX3 expression in oesophageal neoplastic progression, alongside a dynamic inflammatory 120 
cell infiltrate adjacent to BO mucosa, we demonstrate novel mechanistic insights into the 121 
pathogenesis of BO and malignant transformation. Notably, we have identified a protein 122 
signature strongly associated with presence of progressive disease at time of sampling, even 123 
although the dysplastic or carcinomatous mucosa is not apparent in the endoscopic biopsies 124 
obtained, and therefore identifying high risk individuals that need further assessment. These 125 
data from this discovery cohort offers high translational potential as a novel biomarker to 126 
predict presence of disease progression not histologically sampled by random biopsies, offers 127 
a new biomarker to aid diagnosis of dysplasia and uncovers a novel target pathway to develop 128 
treatment strategies to deter malignant transformation in BO.  129 
 130 
METHODS 131 
Tissue Specimens 132 
Formalin-fixed paraffin-embedded tissue was sourced from the Grampian 133 
Biorepository (n=218 total, Figure 1). Tissue cores within a pre-published tissue microarray33 134 
representing 58 oesophageal adenocarcinomas, 15 normal oesophageal mucosa, 24 normal 135 
gastric mucosa and 14 BO mucosa adjacent to oesophageal adenocarcinoma were assessed. 136 
In addition, 107 endoscopically retrieved biopsy specimens with a histological diagnosis of BO 137 
were analysed; 78 endoscopically retrieved biopsies of BO from patients who had not 138 
progressed, 15 endoscopically retrieved biopsies displaying low grade dysplastic BO, 14 139 
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endoscopically retrieved biopsies of non-dysplastic BO adjacent to an area of dysplasia. On 140 
average, 3 biopsies were retrieved per patient. In total, 121 tissue samples of BO were 141 
included in the analysis. The histological diagnosis of each tissue was confirmed by an expert 142 
gastrointestinal pathologist (GIM). 143 
 144 
Tissue Microarray 145 
Tissue cores were obtained at time of surgical resection for oesophageal or gastric 146 
cancer between 2004 and 2010 at Aberdeen Royal Infirmary as previously published.33 147 
Supplementary Table 1 describes clinico-pathological parameters and their relationship with 148 
overall survival and validates the TMA as representative of pathology.  149 
 150 
Immunohistochemistry.  151 
Intensity of epithelial nuclear and cytoplasmic expression of target proteins (HMGB1, 152 
p53 and RUNX3) were each assessed immunohistochemically in all tissue specimens (n=218). 153 
Stromal inflammatory cell phenotype was assessed in BO (n=121). Expression of CD20, CD4, 154 
CD8 and Foxp3 were used to identify B lymphocytes, and helper, cytotoxic and regulatory T-155 
lymphocyte cell subsets, respectively. Antibody characteristics, dilutions, positive controls 156 
and methods of antigen-retrieval are outlined in Supplementary Table 2. In total, 1294 stained 157 
tissue sections were analysed.  158 
4µm serial tissue sections were cut and placed onto 3-aminopropyltriethoxysilane-159 
coated slides for immunohistochemical analysis. Specimens were dewaxed in xylene, 160 
rehydrated in alcohol and subject to heat-mediated antigen retrieval by microwaving at 800W 161 
for 20 minutes in either 10mM citrate (pH6) or EDTA (pH 7.8) buffer. Immunohistochemistry 162 
was performed using the Dako Autostainer and Dako EnVision+™ peroxidase-linked, biotin-163 
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free synthesis (Dako, Ely, UK) with 3’-3’-diaminobenzidine as chromogen.34,35 Positive and 164 
negative (exclusion of primary antibody) controls were included within each experiment.  165 
 166 
Evaluation of Immunostaining 167 
Epithelial proteins (HMGB1, p53, RUNX3) 168 
All stained specimens were independently assessed under light microscopy by two 169 
observers (RJP and DPB or MHM). Epithelial intensity and location of HMGB1, p53 and RUNX3 170 
expression was assessed using a semi-quantitative, previously published scoring methodology 171 
of absent, weak, moderate or strong immunopositivity in nuclear and cytoplasmic 172 
compartments.34,36 The intensity score within the area of strongest immunopositivity per 173 
sample was independently recorded by observers. Discordant scores were reviewed and 174 
resolved by discussion. An expert gastrointestinal pathologist (GIM) reviewed and discussed 175 
specimens that remained unresolved. Observers scored blind to clinico-pathological data. 176 
 177 
Stromal Immune cell phenotype 178 
The number of CD20+, CD4+, CD8+ and Foxp3+ stromal lymphocytes were assessed as 179 
previously published37 in normal oesophageal and gastric mucosa (representing normal 180 
squamous and normal glandular epithelium, respectively) versus BO tissue samples. The 181 
number of positively stained lymphocytes were counted in one high-power field at 182 
magnification X40 within the area of most positive lymphocyte infiltration, immediately 183 
adjacent to the appropriate histological epithelial compartment. 184 
 185 
Statistical Analysis.  186 
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All statistical tests were performed using IBM® SPSS® Statistics (Version 24.0.0.0) and a two-187 
tailed alpha was set at 0.05. 95% confidence intervals are included where appropriate. The 188 
association of epithelial HMGB1, p53 and RUNX3 expression with tissue histology or clinico-189 
pathological parameters was evaluated using χ2 and Fisher’s exact tests. Associations 190 
between protein expression or clinicopathological data and survival was assessed using 191 
Kaplan-Meier survival analysis, log-rank tests and Cox-regression analysis. Mann Whitney-U 192 
tests and Kruskal Wallis test with Bonferroni correction was used to assess for associations 193 
between lymphocyte populations and histological cell types in normal and BO specimens. 194 
Samples were analysed as absent & weak versus moderate & strong immunopositivity. To 195 
ensure comprehensive assessment, three further analysis methodologies were used 196 
(immunonegativity versus immunopositivity; absent versus weak versus moderate versus 197 
strong; and strong versus all other intensities), as previously published (Supplementary Tables 198 
3-5).36,38 Results presented in the paper represent absent & weak versus moderate & strong 199 
intensity expression comparisons, and refer to supplementary methodologies when 200 
appropriate. The number of specimens per analysis varied and are declared throughout. This 201 
was due to the finite nature of paraffin block tissue, incorrect tissue type on the slide or 202 
absent or folded specimen. 203 
 204 
205 
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RESULTS 206 
Representative photomicrographs of epithelial target protein expression and 207 
frequency distribution of intensity expression are reported in Figure 2, Supplementary Figure 208 
1 A-G, and Figure 3, respectively. Statistical comparative analyses are detailed in Table 1 and 209 
Supplementary Tables 3-5. 210 
 211 
Dynamic subcellular expression of HMGB1 is associated with oesophageal neoplastic 212 
progression  213 
As expected from its known biology, HMGB1 was strongly expressed in the nuclei of 214 
normal oesophageal epithelium. This expression was reduced in intensity upon metaplastic 215 
change to non-dysplastic BO (p=0.019). In contrast, HMGB1 was not expressed or expressed 216 
weakly in the cytoplasm of normal oesophageal epithelium. However, cytoplasmic expression 217 
increased in intensity in both non-dysplastic and dysplastic BO (both p<0.001) and remained 218 
present in oesophageal adenocarcinoma, although weaker in intensity to non-dysplastic BO 219 
(p=0.001) and dysplastic BO (p=0.002). Oesophageal adenocarcinoma expressed stronger 220 
cytoplasmic HMGB1 compared to normal epithelium (p=0.002).  221 
On extended analysis, nuclear HMGB1 expression intensified (p≤0.008) and 222 
cytoplasmic expression intensity increased further in foci of dysplasia (p≤0.002) compared to 223 
non-dysplastic BO (Supplementary Table 3).  224 
 225 
HMGB1 expression intensity in BO indicates presence of histologically distinct progressive 226 
oesophageal neoplasia 227 
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There was an increased intensity of nuclear HMGB1 in the background BO in those 228 
that had progressed to either dysplasia (71%) or cancer (67%) compared to BO from non-229 
progressors (27%), p≤0.017 and p=0.024, respectively (Supplementary Table 3). 230 
In addition, patients who had progressed to cancer also expressed weaker epithelial 231 
cytoplasmic HMGB1 in their background BO (absent + weak intensity in 67%) compared to 232 
patients who did not have malignancy (absent + weak intensity in 24%), p=0.015. Cytoplasmic 233 
expression of HMGB1 was similar in background BO whether dysplasia was present or not. 234 
Therefore, this data reveals a subcellular dynamic localisation and change in 235 
expression intensity of HMGB1 in oesophageal neoplastic progression. These changes were 236 
demonstrable in background BO when dysplasia or cancer was present outside the 237 
histologically sampled mucosa. In light of this finding, we then explored the biological cellular 238 
consequences of this HMGB1 expression signature with initial focus on expression of key 239 
downstream effector protein expression. 240 
 241 
Epithelial nuclear and cytoplasmic p53 expression is associated with oesophageal neoplastic 242 
progression  243 
Nuclear p53 was absent in the majority (80%) of normal epithelium and emerged in 244 
dysplastic BO (87% as moderate + strong expression), p<0.001, as expected. Oesophageal 245 
adenocarcinoma expressed stronger nuclear p53 compared to normal mucosa (p=0.002) and 246 
non-dysplastic BO (p<0.001), and weaker nuclear p53 expression compared to dysplastic BO 247 
(p=0.006). This expression pattern was similar for p53 within the cytoplasmic cellular 248 
compartment. Notably, as identified in HMGB1 expression analysis, p53 expression was 249 
associated with presence of neoplastic progression even although this was not histologically 250 
present in the endoscopically sampled mucosa; patients who had progressed to dysplasia 251 
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expressed stronger nuclear p53 in their background BO epithelia (50% moderate + strong 252 
intensity), compared to patients who had not progressed (9% moderate + strong intensity), 253 
p=0.001. 254 
 255 
Weak intensity of epithelial nuclear RUNX3 emerges in dysplastic BO  256 
RUNX3 was not expressed in normal epithelium, and rarely (<3%) in non-dysplastic BO 257 
or oesophageal adenocarcinoma epithelium. There was not a spectrum of intensity profiles 258 
to allow our focussed absent + weak intensity versus moderate + strong intensity analysis. 259 
Therefore, we employed extended comparison methods (Supplementary Table 5) to assess 260 
presence versus absence and there was emergence of weak intensity of epithelial nuclear 261 
RUNX3 in dysplastic BO, compared to normal mucosa (p=0.013), non-dysplastic BO (p=0.001) 262 
and oesophageal adenocarcinoma (p=0.002). Patients who had progressed to dysplasia also 263 
expressed weak RUNX3 in their background BO compared to non-dysplastic BO in patients 264 
who had not progressed (p=0.001). These data highlights differential expression of this 265 
protein but the weak intensity is not discriminatory for extrapolation of this protein to a viable 266 
biomarker to aid diagnosis and risk stratification.  267 
 268 
Association between HMGB1 and p53 expression in oesophageal neoplastic progression 269 
The literature supports direct interaction between HMGB1 and p53, and HMGB1 and 270 
RUNX3 as discussed previously. Here, we demonstrate significant association between 271 
cellular compartment expression patterns of HMGB1, p53 and RUNX3 in oesophageal 272 
neoplastic progression (Supplementary Tables 6). 273 
 274 
Stromal lymphocytic phenotype 275 
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We were struck by the dramatic loss of nuclear and emergence of cytoplasmic HMGB1 276 
in metaplastic transformation of normal epithelium to BO. To further characterise the 277 
potential biological consequence of this, we defined the surrounding stromal immune cell 278 
phenotype in normal and BO epithelium (Figure 4-5, Supplementary Figure 1I-L and 279 
Supplementary Tables 7 & 8). HMGB1 was strongly expressed in all lymphocytes across all 280 
stages of oesophageal neoplastic progression (Supplementary Figure 1H).  281 
 282 
Changes in stromal lymphocyte phenotype is associated with BO and dysplasia 283 
Compared to normal epithelium, non-dysplastic BO is associated with reduced 284 
lymphocytic infiltration of CD20+ B-cells (p<0.001), CD4+ T-cells (p<0.001) and CD8+ T-cells 285 
(p<0.001). In areas of dysplastic BO there is an increase of CD20+ B-cells (p=0.003) and CD8+ 286 
T-cells (p=0.012) and an increase in Foxp3+ Tregs (p<0.001) compared to non-dysplastic BO. 287 
Individuals with BO who progressed to dysplasia demonstrated an immune cell infiltrate 288 
signature in background non-dysplastic BO characterised by increased CD20+ B-cells 289 
(p=0.038) compared to non-dysplastic BO of non-progressors. Similarly, patients progressed 290 
to adenocarcinoma displayed increased CD20+ (p<0.001), CD4+ (p=0.003) and CD8+ (p=0.014) 291 
lymphocytes in the background non-dysplastic BO compared to non-progressors. 292 
 293 
  294 
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DISCUSSION 295 
This data reveals novel insights into the cellular microenvironment of Barrett’s oesophagus 296 
and oesophageal neoplastic progression, defined as dynamic subcellular epithelial expression 297 
of HMGB1, associated with epithelial p53 expression and a differential adjacent immune cell 298 
phenotype.  299 
We demonstrate that changes in the expression intensity and location of HMGB1 are 300 
particularly relevant in pre-malignant oesophageal pathology and progression towards 301 
malignancy, rather than offering a discriminatory biomarker in cancer itself. This is suited to 302 
use as a prognostic biomarker for risk stratification in BO and to allow better resource 303 
distribution and fits into the current clinical gap.  304 
There are emerging novel technologies in this field for diagnosis and surveillance of BO. 305 
An example currently in clinical trial is the CytospongeTM to obtain oesophageal cells for 306 
cytology analysis with TFF3 biomarker expression39,40 and gene methylation status.41 Our data 307 
demonstrates that cytoplasmic HMGB1 is identified in metaplastic and not normal 308 
oesophageal or gastric mucosa, and therefore there is potential scope for HMGB1 expression 309 
to enhance diagnostic accuracy of these emerging technologies.  310 
Our data reveals that HMGB1 expression in background Barrett’s mucosa can predict the 311 
presence of dysplasia or cancer in histologically distinct mucosa, despite the dysplastic or 312 
carcinomatous epithelium being absent from the endoscopically sampled tissue. This raises 313 
the potential for immunohistochemical detection of HMGB1 expression pattern to be used 314 
clinically in BO as a biomarker of likely focal progression even when biopsies do not include a 315 
focus of dysplasia or cancer. A strong nuclear HMGB1 in BO epithelium in random sampling 316 
biopsies should raise suspicion of progression to dysplasia or cancer even although that 317 
progressive neoplastic focus has not been sampled. To our knowledge, there are currently no 318 
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alternative risk stratification tools in background sampled BO to detect synchronous 319 
progression in clinical practice. This novel risk stratification could potentially impact clinical 320 
management in 3 ways.  321 
Firstly, this HMGB1 expression signature could facilitate a focussed specialist endoscopic 322 
resource to those at perceived greater risk of disease progression, with timely specialist 323 
endoscopic re-assessment and re-biopsy. 324 
Secondly, could this risk expression profile direct specific endoscopic therapy in the 325 
absence of sampled dysplasia or cancer to reduce future risk of malignancy? There has been 326 
debate for some time in the literature for endoscopic ablation in BO without dysplasia as a 327 
cancer prevention strategy42 but this is not thought cost effective43 and has implications for 328 
risk exposure (radiofrequency ablation (RFA) is associated with stricture 5%, bleeding 1%, and 329 
perforation 0.6% in a meta-analysis)44 in a patient population with low risk of progression. 330 
Therefore, an endoscopic ablation strategy for all BO remains controversial and is not 331 
recommended in clinical practice.45 Nevertheless, current endoscopic surveillance with visible 332 
lesion plus quadrantic biopsies remains problematic due to a variety of factors such as 333 
variability in endoscopist expertise at recognising lesions, sufficient representative material 334 
for pathologists in biopsies, and adherence to recommended biopsy protocol with regard to 335 
number and quadrantic approach.45 Therefore, an alternative means to risk stratify 336 
individuals is needed. As an example, Das et al. incorporated previously identified gene 337 
mutations associated with progression risk to denote mutational load and applied Markov 338 
modelling in a hypothetical cohort to predict those at high risk for endoscopic ablation.46 339 
Through cost effectiveness analysis, they demonstrated that this approach, to direct RFA to a 340 
biomarker-identified high risk group, was superior to other surveillance strategies including 341 
current clinical guidelines. There may be potential for our HMGB1 expression profile, easily 342 
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assessed by widely available and affordable modality of immunohistochemistry, to be applied 343 
in this capacity. However, our data suggests that strong intensity of HMGB1 in background 344 
BO is not apparent in all cases. Therefore, this approach requires further assessment of risk 345 
and cost effectiveness.  346 
Thirdly, current guidelines initially suggested endoscopic ablation therapy in patients with 347 
BO and histological evidence of flat high grade dysplasia,8 with amendment recently as new 348 
evidence has emerged to support endoscopic ablation with RFA in patients with histologically 349 
confirmed low grade dysplasia (LGD).47 These updated guidelines were informed by a 350 
randomised controlled multi-centre study where 68 patients with LGD-BO were treated with 351 
either RFA or standard endoscopic surveillance for progression. There was a progression rate 352 
to high grade dysplasia or cancer of 1% versus 26.5% in the RFA treated versus surveillance 353 
group over 3 years, respectively. RFA treatment in these patients was well tolerated and with 354 
low risk of adverse events. The greatest risk was post-RFA stricture in 12% of patients, 355 
requiring endoscopic dilatation.48 There are difficulties and controversies in the histologically 356 
diagnosis of LGD on biopsies due to inter-observer variation, and therefore these current 357 
guidelines suggest the need for histologically proven LGD across at least 2 endoscopies before 358 
RFA. There is potential for our data to be applied to this scenario to aid a diagnosis of dysplasia 359 
based on our identified protein signature of moderate-strong epithelial cytoplasmic and 360 
nuclear HMGB1 and p53, with adjacent Foxp3+ T cell stromal infiltrate in dysplastic BO.  361 
One limitation of this study is the inability to predict future development of progression 362 
at diagnosis as we did not perform temporal analyses in individual patients over repeat 363 
endoscopies. This is an important question and we plan to pursue this in future studies. A 364 
strength is the paired samples from dysplasia or cancer and adjacent background non-365 
dysplastic metaplasia. We acknowledge that the potential biomarkers of oesophageal 366 
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neoplastic progression have been identified from a retrospective cohort and require 367 
independent validation. However, given the small percentage of individuals with BO who 368 
progress to dysplasia or cancer, a prospective study of this nature would be large and over a 369 
long-time frame to reach statistical power. 370 
The stromal microenvironment of a tumour is important in the progression of 371 
malignancy.32 Here, for the first time, we demonstrate a dynamic change in lymphocyte 372 
immune cell phenotype in BO compared to normal mucosa, and dysplastic BO. Lymphocyte 373 
signature in the background non-dysplastic BO was also associated with simultaneous 374 
diagnosis of dysplasia or cancer. We report a significantly lower number of CD20+ B-cells in 375 
non-dysplastic BO compared to normal epithelium, which re-emerge in dysplasia. There have 376 
been no previous studies reporting B-cell infiltrate in BO. However, in oesophageal 377 
adenocarcinoma an increased B-cell density was associated with a better survival.49 In a meta-378 
analysis of 22 studies including over 2000 patients with oesophageal cancer, Zheng et al. 379 
reported that tumour infiltrating lymphocyte density was associated with better survival, with 380 
particular association seen with CD8+ and Foxp3+ cells.50 Infiltrating T-cells change in subtype 381 
from oesophagitis to BO to malignancy with a differential cytokine response, indicating 382 
altered immune cell function in oesophageal neoplastic progression.51 The mechanism and 383 
biological consequence of this dynamic stromal inflammatory infiltrate in oesophageal 384 
neoplastic progression is unknown.  385 
The next focus will be to define the biological consequences of differential HMGB1 386 
expression and inflammatory cell infiltrate in progressive oesophageal pathology. HMGB1 387 
could be protective or pathogenic at a cell level.52 Pro-tumour effects may result from impact 388 
on the stromal inflammatory microenvironment in cancer and through effects on tumour 389 
energy metabolism, tumour progression, tissue invasion, angiogenesis and metastasis.52 Anti-390 
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tumour effects could be a consequence from interaction with various tumour suppressor 391 
proteins such as retinoblastoma and p53. For example, HMGB1 induces a retinoblastoma 392 
protein-dependent G1 cell-cycle arrest in breast cancer, thus functioning as a tumour 393 
suppressor protein and inducer of apoptosis.53 However, these cellular mechanistic studies in 394 
human tissue are challenged by a lack of access to fresh tissue given changes in clinical 395 
practice with increasing oncological focus on treatment of cancer and endoscopic resection 396 
of early lesions, with oesophagectomy rarely performed outside tertiary centres. There are 397 
also limitiations and challenges in available mouse models of BO or BO cell lines that reflects 398 
pathology of the human disease. Endoscopic biopsies can be used in this circumstance but 399 
are limited in tissue yield and can be useful for stromal cell phenotyping, but there may be 400 
limitations for downstream functional studies. However, this is an advancing field and there 401 
is hope for future epithelial directed studies given the emergence of successful protocols for 402 
human BO derived epithelial organoids54 and single cell transcriptomics. 403 
Here, by demonstrating emergence of cytoplasmic HMGB1, nuclear p53 and nuclear 404 
RUNX3 expression in oesophageal neoplastic progression, alongside a dynamic inflammatory 405 
cell infiltrate adjacent to BO mucosa, we offer novel mechanistic insights into the 406 
pathogenesis of BO progression to malignant transformation. This offers translational 407 
potential as a novel biomarker to predict disease progression and a potential novel pathway 408 
to target for new treatment strategies to deter malignant transformation in BO. 409 
  410 
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FIGURE LEGENDS 597 
Figure 1 – Human oesophageal tissue specimens were sourced from the Grampian Tissue 598 
Biorepository (n=218), including 58 oesophageal adenocarcinoma, 39 biopsies of normal 599 
mucosa (15 oesophageal, 24 gastric), 106 non-dysplastic Barrett’s oesophagus (BO) biopsies 600 
(78 from patients with no evidence of dysplasia or cancer, 14 from patients with an adjacent 601 
focus of dysplasia and 14 adjacent BO from patients with adenocarcinoma) and 15 dysplastic 602 
BO biopsies.  603 
 604 
Figure 2 – Dynamic subcellular expression of HMGB1, p53 and RUNX3 is associated with 605 
oesophageal neoplastic progression. Representative photomicrographs across each stage of 606 
oesophageal neoplastic progression demonstrating HMGB1, p53 and RUNX3 expression 607 
profile. Bars below photomicrographs represent the trend in expression pattern throughout 608 
oesophageal neoplastic progression. Associations were analysed by 𝞆𝞆2 and Fisher’s exact test 609 
and p values represent absent + weak vs. moderate + strong protein expression intensity. 610 
Extended analysis revealed p 1≤0.008, 2≤ 0.008, 3≤0.002, 4=0.003, 5≤ 0.004, 6= 0.001 and 7≤ 611 
0.002, and are detailed in Supplementary Tables 3-5.  612 
 613 
Figure 3 – Frequency distribution analysis reveals dynamic subcellular expression of 614 
HMGB1, p53 and RUNX3 is associated with oesophageal neoplastic progression. Intensity 615 
expression of A) epithelial nuclear HMGB1 B) epithelial cytoplasmic HMGB1 C) epithelial 616 
nuclear p53 D) epithelial cytoplasmic p53 E) epithelial nuclear RUNX3 and F) epithelial 617 
cytoplasmic RUNX3, in oesophageal neoplastic progression. Graphs illustrate the frequency 618 
distribution of absent, weak, moderate and strong intensity of immunopositivity in NO – 619 
normal oesophagus, NG – normal gastric, ND BO – non-dysplastic BO, D BO – dysplastic BO, 620 
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ND BO p-dys – non-dysplastic BO in patients with dysplasia, ND BO p-OAC - non-dysplastic BO 621 
in patients with oesophageal adenocarcinoma, OAC – oesophageal adenocarcinoma. Results 622 
of statistical analysis of this data can be viewed in Supplementary tables 3-5.   623 
 624 
Figure 4 – Oesophageal neoplastic progression is associated with a dynamic stromal 625 
lymphocyte phenotype  626 
Representative photomicrographs across each stage of oesophageal neoplastic progression, 627 
representing CD20+ B lymphocytes, CD4+ Th cells, CD8+ cytotoxic T cells and Foxp3+ regulatory 628 
T cells. Bars below photomicrographs represent the trend in respective lymphocyte numbers 629 
throughout neoplastic progression of BO. Analysis by Mann-Whitney-U test.  630 
 631 
Figure 5 – Immunophenotype of Barrett’s oesophagus stromal microenvironment is 632 
dynamic and associated with epithelial HMGB1 expression. Boxplots describing the median, 633 
5h and 95th percentiles for A) CD20+ B-cells B) CD4+ T-cells C) CD8+ T-cells and D) FoxP3+ T-cells 634 
(Tregs) in Barrett’s oesophagus. Analysis by Mann-Whitney-U test or Kruskal Wallis Test with 635 
Bonferroni correction.  636 
 637 
TABLE LEGEND 638 
Table 1 – Dynamic subcellular expression of HMGB1, p53 and RUNX3 is associated with 639 
oesophageal neoplastic progression. Numerical values represent p value from analysis of 640 
absent + weak vs. moderate + strong expression comparisons (𝞆𝞆2 and Fisher’s exact test). 641 
Significant values denoted in bold. NO – normal oesophagus, NG – normal gastric, ND BO – 642 
non-dysplastic BO, D BO – dysplastic BO, ND BO p-dys – non-dysplastic BO in patients with 643 
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dysplasia, ND BO p-OAC - non-dysplastic BO in patients with oesophageal adenocarcinoma, 644 
OAC – oesophageal adenocarcinoma. *no expression. 645 
 646 
